COVAXIN (bbV152), which is being developed for the treatment of children with respiratory diseases, was recently approved by the World Health Organization for emergency use listing. The approval was based on a clinical trial that demonstrated the drug’s efficacy in preventing allergic reactions. OCGN stock surges 8.15% in the pre-market today, jumping to $10.88 per share. COVAXIN, together with other vaccines for children and inactivated polio vaccine, uses the Vero Cell platform. It has been shown to elicit robust antibody titers against various antigens. No serious adverse events were reported in the Phase 2/3 study of COVAXIN for children. There were also no events of special interest.
Ocugen is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines and therapeutics. The company’s lead product candidate, COVID-19, is a pediatric vaccine candidate that was studied in India. COVAXINTM is a vaccine that has been used for the production of polio vaccines for over three decades. It is made using a process known as inactivated polio vaccine manufacturing. Bharat Biotech has submitted a New Drug Submission (NDS) for its lead product candidate, for the treatment of children between the age of 2-18. The submission is based on data from a Phase 2/3 trial conducted in India.